150 related articles for article (PubMed ID: 38466366)
1. Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma.
Fang S; Zheng L; Shu GF; Xiaoxiao C; Guo X; Ding Y; Yang W; Chen J; Zhao Z; Tu J; Chen M; Ji JS
ACS Nano; 2024 Mar; 18(12):8811-8826. PubMed ID: 38466366
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.
Sun H; Meng W; Zhu J; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):643-658. PubMed ID: 35307759
[TBL] [Abstract][Full Text] [Related]
3. Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36.
Fan FS
Tumour Biol; 2023; 45(1):73-80. PubMed ID: 37694331
[TBL] [Abstract][Full Text] [Related]
4. Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy.
Wang H; Zhang X; Zhang Y; Shi T; Zhang Y; Song X; Liu B; Wang Y; Wei J
BMC Cancer; 2024 Apr; 24(1):445. PubMed ID: 38600469
[TBL] [Abstract][Full Text] [Related]
5. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
[TBL] [Abstract][Full Text] [Related]
6. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
8. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
Chen PW; Tseng SY; Chang HY; Lee CH; Chao TH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077166
[TBL] [Abstract][Full Text] [Related]
9. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
13. Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence.
Zhu XB; Xu YY; Li LC; Sun JB; Wang YZ; Chen J; Wang C; Zhang S; Jin LY
Drug Dev Res; 2024 Feb; 85(1):e22131. PubMed ID: 37943623
[TBL] [Abstract][Full Text] [Related]
14. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
[TBL] [Abstract][Full Text] [Related]
15. Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
Leung AKK; Xue YC; de Guzman A; Grzelkovski G; Kong HJ; Genga KR; Russell JA; Boyd JH; Francis GA; Walley KR
Atherosclerosis; 2022 Dec; 362():29-37. PubMed ID: 36207148
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
[TBL] [Abstract][Full Text] [Related]
17. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Macchi C; Ferri N; Favero C; Cantone L; Vigna L; Pesatori AC; Lupo MG; Sirtori CR; Corsini A; Bollati V; Ruscica M
Eur J Prev Cardiol; 2019 Apr; 26(6):578-588. PubMed ID: 30477320
[TBL] [Abstract][Full Text] [Related]
18. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
Cho KH; Hong YJ
Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
